Indication
Treatment-Naive B Cell Malignancies
1 clinical trial
2 products
Clinical trial
Phase I/II, First in Human, Dose Escalation Trial of TL 895 Monotherapy in Subjects With Relapsed/Refractory B Cell Malignancies and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Subjects and Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
NavtemadlinProduct
TL-895